The Cocoon® (from Lonza) is a functionally closed, sterile, efficient manufacturing platform, which combined with our ...

NPR’s Rob Stein was reporting on what he described as “among the most exciting developments in cancer research in years” — a ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing ...

A clinical trial using engineered immune cells to hunt cancer cells has reported impressive results for solid tumours, a type ...

Phase I trial patients experienced shrinkage of brain tumors and extended survival rates beyond the standard prognosis of one ...

One of the key advantages of CAR T-cell therapy is that it does not cause the side-effects associated with chemotherapy and ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

During a live event, Konstantinos Sdrimas, MD, asked participants what community oncologists should consider when referring ...

CAR T-cell therapy shows promise in treating gastric, brain tumors, with significant results in clinical trials.

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain ...

This research roundup discusses researchers’ attempts to find a treatment for a “brain fog” that comes with CAR T-Cell ...